You just read:

Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop TAS6417, Novel EGFR Tyrosine Kinase Inhibitor

News provided by

Taiho Pharmaceutical Co., Ltd., Cullinan Oncology, LLC

Feb 05, 2019, 03:00 ET